Human Bordetalla Pertussis IgA Lateral flow dipstick kit 5773

$487.00

Summary

Mikrogen diagnostik lateral flow device (dipstick) for research use (RUO)
Human Bordetalla Pertussis IgA Lateral flow dipstick kit 5773
Suitable for IgA detection
Ready-to-use
20 tests

SKU: 5773 Category: Mikrogen kits Tags: Bordetella pertussis, IgA, Lateral Flow Dipsticks

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Human Bordetalla Pertussis IgA
species reactivity	Bordetella pertussis, Bordetella parapertussis
applications	Lateral flow (dipstick)
assay type	Indirect & qualitative
available sizes	2x 20 test kits

Human Bordetalla Pertussis IgA Lateral flow dipstick kit 5773

Assay type
Sandwich assay, lateral flow (dipstick)

Research area
Infectious Disease

Sample type
Serum, plasma, whole blood

Components

10X Wash Buffer	100 mL
TMB Substrate	40 mL
Milk Powder	5 g
Instructions for Use	1 Each
Evaluation Form	1 Each
Test Strips	2 kits of [2 Vials x 10 Each]
Anti-Human IgA Conjugate	500 µL
Positive Control	140 µL
Negative Control	140 µL

Storage
Store at 2-8°C.

Additional information

The Mikrogen recomLine Bordetella pertussis tests contain the two antigens pertussis toxin (PT or PT-100), specific for B. pertussis, and filamentous hemagglutinin (FHA), which all representatives of the Bordetella species possess.

After screening by ELISA, the recomLine Bordetella pertussis IgG, IgA can be used to clarify inconclusive or positive ELISA results to determine infection status.

Advantages

PT-100 antigen concentration calibrated by the WHO standard.
IgG antibody concentrations of ?100 IU/ml against pertussis toxin - indicating acute pertussis infection.
Antibodies against filamentous hemagglutinin antigen (FHA) indicate Bordetella species infection.
Separate detection of IgG and IgA antibodies.
Simple and clear interpretation due to easy-to-read banding.
Partial and full automation, software-based evaluation (recomScan), and integration with laboratory information system possible.
Highest sensitivity and specificity through use of recombinant antigens:

Bands

Antigen	Abbreviation	Molecular Weight [kDa]
Filamentous hemagglutinin	FHA	35
Pertussis toxin*	PT-100, PT	28, 23, 22, 11.7, 9.3 (5 subunits)

target relevance

human antibody anti-Bordetella pertussis

Bordetella pertussis

Description
Bacterium that causes whooping cough (pertussis)

Structure
Bordetella pertussis is a small, Gram-negative, aerobic coccobacillus belonging to the family Alcaligenaceae. The bacterium is a strictly human pathogen and the primary causative agent of pertussis, commonly known as whooping cough. B. pertussis colonizes the ciliated epithelium of the upper respiratory tract through the action of multiple adhesins, including filamentous hemagglutinin, pertactin, and fimbriae. The organism produces several virulence factors, most notably pertussis toxin, adenylate cyclase toxin, and tracheal cytotoxin, which interfere with host immune responses and contribute to respiratory tract damage. Despite widespread vaccination programs, Bordetella pertussis remains a significant cause of respiratory disease worldwide, particularly among infants and inadequately vaccinated populations.

Diagnosis
The diagnosis of Bordetella pertussis infection is performed using microbiological, molecular, and serological methods. Polymerase chain reaction (PCR) testing of nasopharyngeal specimens is the preferred laboratory method during the early stages of infection due to its high sensitivity and rapid turnaround time. Culture of B. pertussis from nasopharyngeal swabs remains the definitive diagnostic method but is less sensitive and requires specialized media and prolonged incubation. Serological assays, including ELISA-based tests that detect antibodies against pertussis toxin and other bacterial antigens, are useful in later stages of disease when bacterial shedding has decreased. Laboratory diagnosis is particularly important because clinical presentation may overlap with other respiratory infections.

Symptoms
Bordetella pertussis infection is highly contagious and spreads through respiratory droplets generated during coughing or sneezing. Following an incubation period of approximately seven to ten days, disease typically progresses through three stages. The catarrhal stage resembles a common upper respiratory infection with symptoms including runny nose, mild fever, sneezing, and occasional cough. This is followed by the paroxysmal stage, characterized by severe repetitive coughing fits that may be followed by the characteristic inspiratory 'whoop,' post-tussive vomiting, and exhaustion. In infants, apnea may occur and can be life-threatening. The final convalescent stage involves gradual recovery over weeks to months, although coughing episodes may persist. Complications include pneumonia, seizures, encephalopathy, rib fractures, and, particularly in young infants, death.

Data

FAQ & Publications

Frequently Asked Questions

What type of samples can be used with the Human Bordetalla Pertussis IgA Lateral Flow Dipstick Kit 5773?

The kit is compatible with serum, plasma, and whole blood samples for the detection of Bordetella pertussis IgA antibodies.

Which Bordetella species does this lateral flow dipstick test detect?

This kit is reactive to Bordetella pertussis and Bordetella parapertussis species.

How should the Human Bordetalla Pertussis IgA Lateral Flow Dipstick Kit 5773 be stored to maintain its stability?

The kit components should be stored at refrigerated temperatures between 2-8°C to ensure proper stability and performance.

What antigens are used in the kit to detect IgA antibodies against Bordetella pertussis?

The kit utilizes recombinant pertussis toxin (PT-100) and filamentous hemagglutinin (FHA) antigens to specifically detect IgA antibodies against Bordetella pertussis.

Is this Human Bordetalla Pertussis IgA Lateral Flow Dipstick Kit suitable for quantitative or qualitative analysis?

This assay is designed as an indirect and qualitative sandwich lateral flow test for research use only, providing qualitative detection of IgA antibodies.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
This product has moved to a digital protocol. Please use the URL provided on the product packaging to access the electronic Instructions for Use (eIFU). 5773 protocol